Healthcare Industry News: bladder cancer
News Release - January 29, 2009
Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer DetectionBTA stat(R) Test Detects Bladder Tumor Associated Antigen in Urine
CORTLANDT MANOR, N.Y., Jan. 29 -- (Healthcare Sales & Marketing Network) -- Polymedco, Inc. is pleased to announce the direct availability of the BTA stat(R) test from our sales force -- The BTA stat(R) test is a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine. The specificity of the BTA stat(R) test was 93 - 95% in patients with non-genitourinary diseases and cancers and healthy individuals tested as part of a multi-center study. The test has a sensitivity that is considerably higher than voided urine cytology, enabling detection of recurrent early stage and grade cancers that cytology often misses. Requiring three drops of urine, the result is delivered in only five minutes. The appearance of a line in the patient window indicates a positive result. The BTA stat(R) test requires one voided urine sample with no sample preparation. The BTA stat(R) test is CLIA waived and also available for prescription home use.
bladder cancer is the fourth most common cancer among men. Over 14,000 deaths are expected this year and 68,810 new cases will be diagnosed with the disease. It has a 5-year survival rate of 94% if caught early and recurs in over 88% of patients within fifteen years, calling for regular testing and lifelong management.
Polymedco, Inc. is one of the leading marketing and distribution companies in the clinical laboratory marketplace. Since the company's inception in 1980, Polymedco has evolved into a highly skilled and successful sales, marketing and manufacturing organization.
For More Information, please contact Polymedco at 800-431-2123 or 914-739-5400, or visit our website: www.polymedco.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.